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ABSTRACT 
Background: The evidence base to guide therapeutic choices for patients with chronic and 
treatment refractory depression (TRD) remains weak. There is limited comparative information 
available to guide choice of intervention for patients with the most severe and disabling forms 
of illness. 
Objectives: To describe the 12-month clinical outcomes for patients with chronic TRD treated 
with Anterior Capsulotomy [ACAPS] (n=5), Anterior Cingulotomy [ACING] (n=5), or Vagus Nerve 
Stimulation [VNS] (n=5). 
Methods: A retrospective, consecutive, case series comparison. 
Results: With clinical response defined as ≥50% reduction from baseline MADRS score, 
response rates were: ACAPS (40%); ACING (60%); and VNS (20%). Adverse effects from all three 
procedures were relatively mild, consistent with previous reports and, in most cases, transient. 
Adverse effects from VNS were related to active stimulation, modifiable and diminished in 
severity over time. There were no deaths. 
Conclusions: Although a small sample, our data represent a unique comparison of ACAPS, 
ACING and VNS for chronic TRD. The three cohorts were broadly equivalent in terms of baseline 
clinical characteristics, indices of chronicity, illness severity, and estimates of previous failed 
treatments. ACING and ACAPS, but not VNS, were associated with favourable response rates at 
12 months. 
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INTRODUCTION 
Comparisons between neurosurgical interventions for depression 
There is no robust comparative literature for contemporary ablative surgery for the treatment 
of chronic, severe, treatment-refractory depression. 
Kullberg [1] reported outcomes for a series of patients with different diagnoses treated 
by Anterior Capsulotomy (ACAPS) and Anterior Cingulotomy (ACING) (n=13 in each cohort) after 
at least 1 year follow-up. Using a categorical grading of function and perceived improvement, 
patients in the ACAPS cohort were considered to have experienced marginally superior 
outcomes, but at the expense of poorly specified and unmeasured “personality changes”. 
Unfortunately, the descriptions of the characteristics of these patients are difficult to reconcile 
with contemporary diagnostic concepts (“…the target symptom was anxiety, on the basis of 
neurosis in 13, and early stage schizophrenia in one.”) Importantly, there were no useful details 
with respect to chronicity, severity, or previous treatments, and lesion topography was 
unavailable. 
Attempts to synthesise clinical outcomes in a manner that permits direct comparison [2-
4] are fraught with bias, inaccuracy and uncertainty. For example: key clinical characteristics of 
patient populations are unreported or non-standardised; lesion characteristics rarely reported; 
and post-operative management plans rarely specified, let alone standardised. 
Given the proliferation of neurosurgical interventions, primarily DBS-based, for 
psychiatric disorders since Nuttin and colleagues published their seminal report of apparent 
clinical effect of stimulation of the anterior limbs of the internal capsules in patients with OCD 
[5], there has been a compelling need to establish the relative efficacy of different treatments 
and targets to ensure that patients can provide informed consent to the procedure proposed. 
Establishing with confidence the comparative efficacy of different neurosurgical procedures for 
the management of TRD, as with any other clinical presentation, would require randomisation 
of patients meeting clearly defined study entry criteria, with a degree of standardisation of 
baseline illness and personal characteristics. 
Unfortunately, there are no contemporary examples of such robust comparative 
studies. Indeed, three recent pivotal studies to test the efficacy of neurosurgical stimulation 
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treatments against even sham/placebo treatment have proven negative. For example, active 
VNS failed to differentiate from implantation plus sham stimulation in a large RCT [6] and there 
have been two large, multicentre, randomised, controlled trials evaluating the efficacy of DBS 
targeting either subgenual cingulate white matter tracts or ventral striatum/ventral capsule 
that were either negative [7] or discontinued in the light of futility analyses that suggested lack 
of efficacy [8]. 
Although post hoc sub-group analyses no doubt proceed apace to identify possible 
anatomical and stimulation parameter relationships that might reveal a covert therapeutic 
signal with both of these treatments, it is important to consider the possibility (or probability) 
that these therapies confer no benefit beyond those of non-specific  / placebo effects.  
Anterior Capsulotomy (ACAPS) 
Thermal anterior capsulotomy was introduced by Lars Leksell in the 1950s for the treatment of 
and outcome in psychiatric illness (including 19 patients with depression) were reported by 
Torsten Herner in 1961 [9]. 
The lesions are placed in the anterior one third of the anterior limb of the internal 
capsule, and the target fibres connect the ventromedial orbitofrontal cortex and anterior 
cingulate cortex with the thalamus, amygdala, and hippocampus. 
There are relatively few long-term follow-up studies reporting clinical outcomes for 
ACAPS for depression, but recent reports would suggest response rates of 50% [10]. Whilst 
ACAPS for anxiety disorders may be associated with an less favourable adverse effect profile 
[for example, 11], long-term follow-up of 20 patients with chronic, treatment-refractory 
depression failed to identify negative changes in personality or neurocognition [10]. 
Anterior Cingulotomy (ACING) 
The anterior cingulotomy was introduced by Foltz and White in 1962, again for chronic pain 
[12]. The target site is similar to that of Anterior Cingulectomy, developed 10 years previously 
[13] and was popularised in the US by Ballantine for psychiatric illness and chronic pain [14]. 
The lesions of Cingulotomy target the cingulum bundle within the anterior cingulate gyrus, and 
also involve part of the anterior cingulate cortex. 
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Response rates to ACING for depression are typically in the region of 30% - 50% [15-17], 
although multiple factors may influence likelihood of response. 
Vagus Nerve Stimulation (VNS) 
VNS involves implantation of a pulse generator (similar in size to a cardiac pacemaker) in 
subcutaneous tissues in the left anterior chest wall. Electrodes are tunnelled under the skin and 
connect the pulse generator to the left vagus nerve in the neck. Typically for the treatment of 
depression, the pulse generator stimulates the nerve for 30 seconds every 5 minutes at a 
current of 1-2 milliamps. 
Whilst a variety of reports of clinical outcome of VNS suggest response rates of 40%-
50%, most patients in clinical studies did not have the kind of chronic, treatment-refractory 
depression typically seen in those undergoing ablative neurosurgery. However, in such patients 
response rates may still lie within the region of 30% [18] 
METHODS 
Objective 
To describe the clinical outcomes at 12 months for consecutive patients with chronic, 
treatment-refractory depression (TRD) referred to the Dundee Neurosurgery for Mental 
Disorder / Advanced Interventions Service and ultimately treated between 1997 and 2004 with 
either Anterior Capsulotomy [ACAPS] (n=5), Anterior Cingulotomy [ACING] (n=5), or Vagus 
Nerve Stimulation [VNS] (n=5). 
Treatment cohorts 
Each treatment cohort represented the 5 most recent, consecutive, procedures for whom full 
12-month follow-up data was available. Each patient reported here has been included 
previously within larger, single procedure case series [10; 17; 18]. The duration of follow-up 
reported here was limited to 12-months by some patients within each cohort (who were non-
responders) going on to have further ablative procedures. Although there was overlap, the 
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patients were NOT operated on contemporaneously and treatment allocation was NOT 
randomised. 
ACAPS patients were operated on in 1997 and 1998; ACING patients between 1999 and 
2004; and VNS patients between 2001 and 2004. Prior to 1998, the ‘procedure of choice’ in 
Dundee for patients with chronic TRD was ACAPS. In 1998, following reports of the relative 
efficacy and adverse effects of each procedure, a decision was made to switch to ACING as the 
‘procedure of choice’. VNS became available as a treatment option from 2001 and was offered 
to patients as an alternative to ACING. The VNS cohort, therefore, chose this procedure over 
ACING. Also, therefore, the ACING cohort chose this procedure over VNS. 
Inclusion criteria 
All diagnoses were made by experienced clinicians and academic psychiatrists. Each patient met 
criteria for a primary diagnosis of either single episode, or recurrent Depressive Disorder 
according to ICD-10 and DSM-IV with minimum duration of index episode ≥24 months; 
although the actual duration was much longer. All patients were without significant psychiatric 
(Axis-I or Axis-II) or physical comorbidity. Diagnosis was determined in most cases by semi-
structured clinical interviews (in the case of ACING and VNS patients) and was confirmed (in the 
case of the ACAPS patients) using OPCRIT [19]. 
Each patient had experienced very significant social and occupational impairment and 
had failed to sustain meaningful clinical response to a broad range of antidepressant 
medications and to sustained trials of psychological therapy with expert therapists. 
Exclusion criteria 
General exclusion criteria included: failure to satisfy the inclusion criteria regarding primary 
diagnosis; a current diagnosis of substance misuse fulfilling criteria for ICD-10 F10 to F19 mental 
and behavioral disorders due to psychoactive substance use; a diagnosis of organic brain 
syndrome fulfilling criteria for ICD-10 F00 to F09 including Alzheimer’s disease, vascular and 
other dementias; a diagnosis of disorder of adult personality fulfilling criteria for ICD-10 F60 to 
F69; and a diagnosis of pervasive developmental disorder fulfilling criteria for ICD-10 F84. Other 
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specific exclusion criteria included previous ablative neurosurgery and previous vagotomy 
surgery (for the VNS cohort). 
Ethical issues 
Ten patients (66.7%) were not subject to any mental health legislation. Five patients (all 
ablative procedures; 33.3%) were subject to detention under either English or Scottish Mental 
Health legislation at time of surgery. 
All patients were required to provide informed consent for surgery. In compliance with 
relevant Scottish Mental Health Legislation and best practice, all patients in receipt of ablative 
surgery were reviewed by Commissioners appointed by the Mental Welfare Commission for 
Scotland and independent clinical (and lay) opinion provided on adequacy of previous therapy; 
the suitability of the proposed treatment and capacity to provide informed consent to surgery. 
Surgical Procedures 
All surgical procedures were conducted under general anaesthesia. Volumetric CT and MRI 
images for ablative surgery were obtained parallel to the intercommissural plane for each 
patient and merged using the FrameLink Stereotactic Linking System (version 4. Medtronic Inc, 
Minneapolis, Minnesota, USA).  For ACAPS surgery, details of surgical procedure are as for the 
larger case series reported by Christmas et al [10]. The bilateral target was 19-21 mm anterior 
to the anterior commissure. A 3 mm wide, 6 mm long radiofrequency probe was sited within 
the target such that its tip was at the inferior aspect of the target volume. Single lesions were 
made in each hemisphere by heating the probe to 70˚C for 90 s using a radiofrequency lesion 
generator (Radionics, Burlington, Massachusetts). Additional bilateral lesions were similarly 
made such that the initial lesion was extended caudally to produce a total lesion within each 
capsule of approximately 18-20 mm in height and 8 mm in width. 
For ACING surgery, details of surgical procedure were as for Steele et al [17]. A 
stereotactic frame ring was fixed parallel to the glabella-inion line and volumetric 
magnetisation prepared rapid gradient echo (MPRAGE) and coronal T2 magnetic resonance 
imaging (MRI) sequences, plus an axial computed tomography (CT) scan, 1 mm thick at zero 
angle, were obtained. Images were merged on a workstation using FrameLink software (version 
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4, Medtronic Inc, Minneapolis, Minnesota, USA). The bilateral targets were points 1 mm above 
the roof of the lateral ventricle, 7 mm lateral to the midline, and 20 mm posterior to the tip of 
the frontal horn. Radiofrequency lesions were made using a 6-mm exposed tip electrode and a 
radiofrequency lesion generator (Radionics, Burlington, Massachusetts). For each lesion, the tip 
was heated to 70°C for 90 seconds, repeated twice. The lesion volume contained both cingulum 
bundle and cortex. 
For VNS surgery, details are as per Christmas et al [18]. VNS involved intermittent 
electrical stimulation of the left cervical vagus nerve using an implanted pulse generator in the 
left anterior chest wall using a commercial device, the NeuroCybernetic Prosthesis (NCP®) 
system (Cyberonics Inc., Webster, Texas, USA). Bipolar electrodes were wrapped around the 
left vagus nerve in the neck, near to the carotid artery, and connected to the stimulus 
generator. Thereafter, the treatment involved an intermittent stimulation of the afferent fibres 
within the left vagus nerve, with the intensity and frequency of generator firing controlled 
through the use of a telemetric wand connected to a personal computer. Stimulation 
parameters for the VNS-treated patients are shown in online table 1. 
Clinical assessments 
Objective assessments 
Depressive symptoms were rated using the 17-item Hamilton Rating Scale for Depression 
[HRSD-17; 20] and the Montgomery-Åsberg Depression Rating Scale [MADRS; 21]. Global 
clinical outcomes were assessed using the Clinical Global Impression [22]. 
Self-report measures 
The Beck Depression Inventory [BDI-II; 23] was used as the primary self-report depressive 
symptom measure for these cohorts. 
Personality assessments 
Personality was assessed in the majority of patients using the Personality Assessment Scale 
[24], completed with the patient and/or informant. 
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Categorical Outcomes 
Standard criteria were used to define response and remission. ‘Response’ on the HRSD-17 was 
defined as ≥ 50% improvement from baseline score with ‘remission’ defined as a score of ≤ 7 at 
12 month follow-up. ‘Response’ on the MADRS was defined as ≥ 50% improvement from 
baseline score with ‘recovery’ as a score of ≤ 10 at 12 months. ‘Response’ on the CGI-I was 
defined as achieving a score of 1 or 2 at 12-month follow-up. 
Lesion topography 
In order to calculate lesion locations, T2-weighted images were spatially normalised to the SPM 
T2 template (MNI space) and resliced to form 1mm isotropic voxels using SPM-2 [25]. For each 
scan, the centre of the lesion was estimated using regions of interest (ROI) created using 
MRIcro software [26]. Coordinates were reported in MNI space. 
MRI scans were, unfortunately, unavailable for one ACAPS participants who was 
unwilling to attend Dundee for assessment. Clinical assessments were therefore completed at 
home. 
Statistical analysis 
Missing data were unavailable for a small number of cases. Baseline HRSD-17 scores and 
baseline BDI score were missing for one participant. These were imputed from MADRS score 
using regression models developed from contemporaneous HRSD-17, MADRS, and BDI-II scores 
in 256 patients (in the case of MADRS to HRSD-17) and 68 patients (in the case of MADRS to 
BDI-II). R-squared scores were 0.843 and 0.735 respectively, demonstrating the robustness of 
the model.1 
Twelve-month HRSD-17 scores were missing for two participants and 12-month BDI-II 
scores were missing for five patients. Again, these were imputed from MADRS scores. 
Statistical analysis was performed using R software [27]. Normality of data was 
examined using the Shapiro-Wilk test and means ± SD were reported for normally-distributed 
data, and medians (interquartile range) were reported for non-parametric data. Comparisons 
                                                     
1 Available on request. 
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between groups were made using Chi-squared tests for categorical data, one-way ANOVA for 




Detailed patient characteristics are summarised in online table 2. 
The diagnostic breakdown of patients was as follows: F33.2 (Episode, severe without 
psychotic symptoms), N=2; F33.1 (Recurrent, moderate), N=4; F33.2 (Recurrent, severe without 
psychotic symptoms), N=8; F33.3 (Recurrent, severe with psychotic symptoms), N=1. 
Categorical outcomes 
Categorical outcomes are summarised in online table 3 and show that ACAPS was associated 
with 2/5 (40%) patients achieving symptom improvement consistent with response and 
remission. This improvement was consistent using the HAMD17, the MADRS and the CGI-I. 
ACING was associated with 3/5 (60%) patients achieving symptom improvement consistent 
with response. One (20%) of these patients also met criteria for remission. Again this was 
observed consistently using the HAMD17, the MADRS and the CGI scales. VNS was associated 
with 1/5 (20%) patients meeting criteria for response on the MADRS and CGI, but not on the 
HAMD17. There were no remitters in the VNS cohort at 12m. 
This difference in the levels of improvement observed across the three cohorts was also 
confirmed by the magnitude of changes observed in estimated depression symptom burden 
(see online table 4). Absolute and percentage reductions in symptom burden in the ACAPS and 
ACING cohorts at 12-months were substantially larger than in the VNS patients (see online 
table 5). 
Lesion topography 
MNI coordinates of ACAPS and ACING lesions are shown below in online table 6. ACAPS and 
ACING lesion locations are shown on a spatially normalised brain in online figures 1 and 2. 
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Adverse effects 
All adverse effects identified and reported immediately post-surgery and at 12-month follow-up 
period are summarised in online table 7. There were no deaths during the 12-month follow up 
(still true at time of writing). The only neurological event of note was a single post-operative 
seizure. 
As might be predicted, ablative neurosurgery was associated with a greater burden of 
acute adverse effects in the form of headache and two of the ACAPS patients experienced some 
post-operative confusion. One ACING patient experienced a single post-operative seizure that 
did not require ongoing anticonvulsant therapy. At 12-month follow up, one patient described 
intermittent troublesome nausea and another an episode of urinary retention. (N.B. continuing 
intermittent urinary difficulties have required urological investigation). Subjectively, one ACAPS 
patient complained of concentration and memory difficulties although evidence of consistent 
neuropsychological change following ablative neurosurgery was not found and is summarised 
elsewhere [10; 17]. 
The burden of adverse effects experienced by the VNS patients was low and restricted 
to when stimulation was active. All patients managed to tolerate stimulation at a minimum 
output current of 1.25 mA and adverse effects diminished over time. Stimulation was 
associated with voice change and pharyngeal sensation / discomfort which was generally 
modifiable by reducing the stimulation pulse width. 
DISCUSSION 
We present unique data comparing the 12-month outcomes for three small cohorts of patients 
with TRD following non-randomised neurosurgical intervention with either ablative 
neurosurgery – ACAPS or ACING, or neurostimulation (VNS).  The baseline characteristics of the 
patients within each cohort were consistent with the very chronic, highly disabling and 
markedly treatment refractory forms of illness that are features of the patients that are 
generally considered as potential candidates for neurosurgery within our clinical service. 
There were no statistically significant differences between the cohorts at baseline and 
treatment adequacy was broadly comparable in all groups. 
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Response rates at 12-months were higher for those treated by ACAPS and ACING than 
with VNS. The mean magnitude of change in depression symptom burden was also greater in 
the ACAPS and ACING groups than in those treated with VNS. Although associated with a low 
adverse effect burden, VNS was not associated with a rate of response or degree of functional 
improvement comparable to that seen in patients treated by ablative neurosurgery (40-60%). 
Adverse effect burden within the ACAPS and ACING cohorts was higher than for VNS, but there 
were few persisting unwanted effects and there were no deaths. For patients with TRD of this 
chronicity and severity, and with this degree of functional impairment, ACAPS and ACING both 
appear to be relatively safe and effective interventions. 
VNS is a safe, but relatively less effective intervention and may best be reserved for 
patients with less chronic and refractory forms of TRD. VNS patients here had a median of eight 
previous failed treatments in the current MDE and data from previous outcome studies have 
suggested that VNS response and remission rates decline with increasing levels of treatment 
non-response prior to VNS [28] although the rates of response to VNS in two larger series with 
comparable levels of prior non-response have been around 30-35% [18].  
Limitations 
This is a non-randomised comparison of three small cohorts and follow-up data only relate to 
the first 12-months following surgery. Assessors were not blinded to treatment condition. 
There was a small amount of missing data and adverse effect information was, historically, not 
collected systematically using specific tools designed to identify adverse effects (including at 
baseline). Open study designs such as this are unable to determine if clinical improvement 
reflects genuine response to the intervention or to reflect natural fluctuations in illness severity 
and / or response to non-specific effects (attention, structured care, placebo response etc.). 
Conclusions 
Despite the limitations within the evidence base, the conduct of ablative neurosurgery for 
psychiatric disorders continues. Based upon our small, single centre, non-randomised study of 
patients with chronic, disabling and highly refractory Major Depression, we propose that ACAPS 
and ACING appear more likely to be associated with beneficial clinical response than VNS. 
Comparison of ACAPS, ACING, and VNS | v4.0 
     13 
Therapeutic trials of VNS may more appropriately be considered for patients at an earlier stage 
in the treatment pathway, prior to consideration for ablative surgery. Definitive, and necessary, 
trials comparing DBS / VNS and ablative neurosurgery for chronic and severe refractory Major 
Depression are awaited.  
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